Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level

NCT ID: NCT07046312

Last Updated: 2025-07-01

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 60 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-07-31
• Study Completion Date: 2027-04-30

Brief Summary

The aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain echocardiography

Detailed Description

Previous studies evaluated RV strain for detection of subclinical RV affection due to PAH in systemic lupus erythematosus. However , to our knowledge , the study of RV strain and its possible association with serum endostatin to detect subclinical right ventricular systolic dysfunction and its relation to PAH in PsA patient is still a novel. Our aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain Echocardiography.

To evaluate serum endostatin as an objective biomarker for Pulmonary arterial hypertension.

Conditions

Psoriatic Arthritis (PsA); Subclinical Right Ventricular Systolic Dysfunction

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Control

30 control group matched as regards BMI, age and sex will be subjected to transthoracic echo and measuring serum endostatin level.

No interventions assigned to this group

Cases of Psoriatic arthritis patients

30 PsA patients will be subjected to transthoracic echo, measuring serum endostatin level and modified composite psoriatic disease activity index

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Psoriatic arthritis patients according to CASPAR criteria
• Psoriatic arthritis patients without overt cardiovascular symptoms
• Patients with age between 20 to 50 years of age

Exclusion Criteria

• Other systemic autoimmune diseases
• Patients with a history of known valvular disease, atrial fibrillation or any other arrhythmia , heart failure, ischemic cardiomyopathy severe obstructive pulmonary diseases and metabolic syndrome.
• Patients with medical disorders as renal, congenital heart diseases, hematological disorders and cancer patients.
• Patients taking certain drugs that have been confirmed to be risk factors for PAH such as appetite suppressant intake drugs (aminorex, fenfluramine derivatives and benfluorex) and chemotherapeutic agents.
• Family history of myocardial infarction, cerebrovascular disease or sudden death before the age of 65y in females and 55 y in males.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ain Shams University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Ain Shams University

Cairo, Abbassia, Egypt

Countries

Egypt

Central Contacts

Dina Maamoun ElHadba, MSc Ain Shams University

Role: CONTACT

DinaElhadba@med.asu.edu

01006780166

Other Identifiers

MD13/2025

Identifier Type: -

Identifier Source: org_study_id